Skip to content

Study · Randomized controlled trial · n = 1,071 · 2019

2 results

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK and 5 more

Show all authors

Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A

The Lancet. Oncology19 Dec 2018Cited by 85 (Europe PMC)

PMID30579763 (opens in a new tab)DOI10.1016/s1470-2045(18)30757-5 (opens in a new tab)PepBankPUB-30579763
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with locally advanced prostate cancer, mortality from prostate cancer was 9·7% with 18 months versus 13·3% with 6 months of suppression.

    In plain wordsIn men with prostate cancer, longer leuprorelin treatment reduced prostate cancer mortality compared with shorter treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseProstate cancer-specific mortality
    Study

    n = 1,071

    Comparator
    6 months of leuprorelin with radiotherapy
    Analysis
    Primary
    Outcome group
    Mortality · Cancer
    Studied dose
    22·5 mg every 3 months · intramuscular · 18 monthsAs given in this study (human).

    Measurements

    Mortality
    9.7%
    18 months
    Mortality
    13.3%
    6 months
    Absolute difference
    3.7%
    duration contrast
    sHR
    0.7
    duration contrast
    95% CI
    0.5 to 0.98
    sHR
    Adjusted p
    0.035
    duration contrast

    Source sentences

    Summary
    When analysed by duration of androgen suppression, the adjusted cumulative incidence of prostate cancer-specific mortality was 13·3% (95% CI 10·3-16·0) for 6AS+RT versus 9·7% (7·3-12·0) for 18AS+RT, representing an absolute difference of 3·7% (95% CI 0·3-7·1; sub-hazard ratio [sHR] 0·70 [95% CI 0·50…
    5 context sentences
    Summary · context
    The total number of deaths was 375 (200 men receiving 6AS+RT and 175 men receiving 18AS+RT), of which 143 (38%) were attributable to prostate cancer (81 men receiving 6AS+RT and 62 men receiving 18AS+RT).
    Summary · context
    For this randomised, phase 3, 2 × 2 factorial trial, eligible men were 18 years or older with locally advanced prostate cancer (either T2b-4, N0 M0 tumours or T2a, N0 M0 tumours provided Gleason score was ≥7 and baseline prostate-specific antigen [PSA] concentration was ≥10 μg/L).
    Summary · context
    Patients in the control group received 6 months of neoadjuvant androgen suppression with leuprorelin (22·5 mg every 3 months, intramuscularly) and radiotherapy alone (short-term androgen suppression [STAS]);
    Summary · context
    this treatment was either followed by another 12 months of adjuvant androgen suppression with leuprorelin (22·5 mg every 3 months, intramuscularly; intermediate-term androgen suppression [ITAS]),
    Summary · context
    the treatment groups were collapsed to compare treatments according to duration of androgen suppression: 6 months of androgen suppression plus radiotherapy (6AS+RT) versus 18 months of androgen suppression plus radiotherapy (18AS+RT)
  2. 02HumanRandomized controlled trialSafety outcome

    In men with locally advanced prostate cancer, 175 deaths occurred with 18 months of androgen suppression versus 200 with 6 months.

    In plain wordsIn men with prostate cancer, deaths numbered 175 with longer leuprorelin treatment and 200 with shorter treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseAll-cause deaths
    Study

    n = 1,071

    Comparator
    6 months of leuprorelin with radiotherapy
    Outcome group
    Mortality · Cancer
    Studied dose
    22·5 mg every 3 months · intramuscular · 18 monthsAs given in this study (human).

    Measurements

    All-cause deaths
    200 deaths
    6AS+RT
    All-cause deaths
    175 deaths
    18AS+RT
    Total deaths
    375 deaths
    both duration groups

    Source sentences

    Summary
    The total number of deaths was 375 (200 men receiving 6AS+RT and 175 men receiving 18AS+RT), of which 143 (38%) were attributable to prostate cancer (81 men receiving 6AS+RT and 62 men receiving 18AS+RT).
    4 context sentences
    Summary · context
    For this randomised, phase 3, 2 × 2 factorial trial, eligible men were 18 years or older with locally advanced prostate cancer (either T2b-4, N0 M0 tumours or T2a, N0 M0 tumours provided Gleason score was ≥7 and baseline prostate-specific antigen [PSA] concentration was ≥10 μg/L).
    Summary · context
    Patients in the control group received 6 months of neoadjuvant androgen suppression with leuprorelin (22·5 mg every 3 months, intramuscularly) and radiotherapy alone (short-term androgen suppression [STAS]);
    Summary · context
    this treatment was either followed by another 12 months of adjuvant androgen suppression with leuprorelin (22·5 mg every 3 months, intramuscularly; intermediate-term androgen suppression [ITAS]),
    Summary · context
    the treatment groups were collapsed to compare treatments according to duration of androgen suppression: 6 months of androgen suppression plus radiotherapy (6AS+RT) versus 18 months of androgen suppression plus radiotherapy (18AS+RT)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00193856

RADAR Trial - Randomised Androgen Deprivation and Radiotherapy

Trans Tasman Radiation Oncology Groupn = 1,071Oct 2003 to Aug 2017

Prostate Cancer

Trial pageClinicalTrials.govUpdated 12 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.